Beigene Stock Current Valuation

688235 Stock   189.78  1.98  1.05%   
Valuation analysis of BeiGene helps investors to measure BeiGene's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of January 21, 2025, Cash is expected to decline to about 3 B. The current year's Change In Cash is expected to grow to about (589.1 M). Fundamental drivers impacting BeiGene's valuation include:
Price Book
10.3356
Enterprise Value
162.4 B
Enterprise Value Ebitda
(86.19)
Price Sales
7.4863
Forward PE
526.3158
Overvalued
Today
189.78
Please note that BeiGene's price fluctuation is very steady at this time. Calculation of the real value of BeiGene is based on 3 months time horizon. Increasing BeiGene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BeiGene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BeiGene Stock. However, BeiGene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  189.78 Real  179.52 Hype  187.48
The real value of BeiGene Stock, also known as its intrinsic value, is the underlying worth of BeiGene Company, which is reflected in its stock price. It is based on BeiGene's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BeiGene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
176.99
Downside
179.52
Real Value
206.58
Upside
Estimating the potential upside or downside of BeiGene helps investors to forecast how BeiGene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BeiGene more accurately as focusing exclusively on BeiGene's fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.52-0.52-0.52
Details
Hype
Prediction
LowEstimatedHigh
184.95187.48190.01
Details

BeiGene Company Current Valuation Analysis

BeiGene's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current BeiGene Current Valuation

    
  162.38 B  
Most of BeiGene's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BeiGene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, BeiGene has a Current Valuation of 162.38 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.

BeiGene Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BeiGene's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics of similar companies.
BeiGene is currently under evaluation in current valuation category among its peers.

BeiGene Fundamentals

About BeiGene Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in BeiGene Stock

BeiGene financial ratios help investors to determine whether BeiGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BeiGene with respect to the benefits of owning BeiGene security.